[Nick Hargrave]

https://www.londonstockexchange.com/news-article/AVCT/full-year-results/16446502

Positive news. CEO transition expected and much needed with investors losing faith in Dr Smith to deliver commercially. Christina has made a positive impression since joining full time. Divestment of Diagnostics is also now firmly on the radar to focus the business although it is likely to deliver a loss on the investment. We would rather the board replaced a director rather than just adding anew one, but if a candidate with the expertise to help where it is sorely needed is found it will be welcome. Clinical trials continue to positively, but we now await news of the expanded preCISION pipeline